An Overview of Ozone Major Autohemotherapy (MAH)

Ozone Major Autohemotherapy (MAH) is a formalized approach for making ozone therapy a productive method of treatment in complementary or integrated medicine around the world. With roots in Germany from the 1950s, MAH is the most accepted method and has more scientific evidence supporting its use than any other ozone administration method for treating the whole body.

In the MAH process, 100-200 mL of the patient’s peripheral venous blood is drawn from a vein using sterile and minimally invasive techniques under very strict medical aseptic conditions. The blood is then mixed with a specific concentration of medical-grade ozone/oxygen in a closed vacuum container and infused back into the patient’s venous circulation by way of an intravenous drip. This entire process occurs under officially documented unified protocols developed by the Italian Scientific Society for Oxygen-Ozone Therapy (SIOOT) as well as other recognized medical organizations, thereby providing standardized operations.

MAH provides positive therapeutic benefit through many biological mechanisms by activating the body’s antioxidant defense system and ultimately increasing the level of antioxidant enzymes, which works to reduce oxidative stress. MAH also modulates the activity of immune cells, helps regulate the inflammatory response, increases blood microcirculation and improves the periphery’s utilization of Oxygen.

Unlike local applications of ozone, MAH has the ability to achieve systemic regulatory actions on the entire body while obtaining cumulative therapeutic results through multiple standardized treatments.

Using MAH therapeutically, clinicians have an effective concurrent treatment for many chronic and sub-non-health disorders. MAH is used primarily as an adjunctive treatment of chronic inflammatory disorders, autoimmune disorders, chronic fatigue syndrome, metabolic disorders and neurological disorders that are caused by oxidative damage. MAH is also used as an adjunctive therapy to rehabilitation following orthopaedic and other chronic disease treatments with good results in reducing chronic pain and increasing the rate of recovery of tissues.

Safety is the central focus in implementing MAH. As a controlled medical procedure, it must be completed by a qualified medical professional, using standardized medical ozone delivery devices and sterile consumables. By strictly controlling the dosage and concentration of ozone used, the potential for a toxic response from being exposed to excessive ozone can be avoided. MAH is considered, in general, to have low potential adverse response rates, generally high levels of tolerability, and acceptable repeatability for the vast majority of patients.

Patients that should not be considered for this therapy are those with severe coagulopathies, in an acute infectious crisis, those with an allergy to ozone and other contraindications to this type of treatment.

In summary, MAH is a well-established, standardized form of systemic ozone therapy, that, when used in accordance with standardized operations and complete pre-treatment screening, there should be a high degree of safety and a high likelihood of therapeutic benefit for patients with chronic inflammatory, immune regulatory and systemic metabolic rehabilitation. The acceptance of MAH as an appropriate complementary and integrative practice exists worldwide.